...and biosimilar manufacturers. The first U.S. biosimilar to make it to the U.S. market, Zarxio filgrastim-sndz...
...U.S., 11 biosimilars of seven innovator products have made it to market. Biosimilars of Neupogen filgrastim...
...competition for over four years, have gained over half of the total market share of filgrastim...

...of non-infringement in favor of the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) for Zarxio filgrastim-sndz...

...products, Neupogen filgrastim, as an example of the success of the U.S. biosimilars market. Zarxio filgrastim-sndz...

...on the U.S. biosimilars market. Its Zarxio filgrastim-sndz, a biosimilar version of Amgen Inc.’s Neupogen filgrastim...

...tests characterizing identity, purity and potency. Side-by-side comparisons of InSCyT-produced G-CSF vs. Amgen Inc.’s Neupogen filgrastim...

...tests characterizing identity, purity and potency. Side-by-side comparisons of InSCyT-produced G-CSF vs. Amgen Inc.’s Neupogen filgrastim...

...or more per month Pfizer Inc. (NYSE:PFE) FDA approves Nivestym filgrastim-aafi, a biosimilar of Neupogen filgrastim...

...they can enter the market. Pfizer Inc.’s Nivestym filgrastim-aafi, a biosimilar of Amgen Inc.’s Neupogen filgrastim...
...it is possible for a biosimilar to gain market share under the current circumstances. Zarxio filgrastim-sndz...
...was the first biosimilar that FDA approved, in March of 2015. Amgen’s neutropenia drug Neupogen filgrastim...

...FDA approved Nivestym filgrastim-aafi from Pfizer Inc. (NYSE:PFE), its biosimilar version of neutropenia drug Neupogen filgrastim...
...division of Novartis AG (NYSE:NVS; SIX:NOVN) markets the only other FDA-approved Neupogen biosimilar as Zarxio filgrastim-sndz...
...Nivestim - EU) filgrastim-aafi Business: Cancer, Hematology Allison Johnson GRAN, Granulokine, Grasin, Neupogen, filgrastim Nivestim, Nivestym, biosimilar filgrastim, filgrastim Amgen...